- Home
- IMMP vs PALI Comparison
IMMP vs PALI Comparison
Compare IMMP & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- PALI
- Stock Information
- Founded
- IMMP 1987
- PALI 1996
- Country
- IMMP Australia
- PALI United States
- Employees
- IMMP N/A
- PALI N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMP Health Care
- PALI Health Care
- Exchange
- IMMP Nasdaq
- PALI Nasdaq
- Market Cap
- IMMP 251.8M
- PALI 212.0M
- IPO Year
- IMMP N/A
- PALI N/A
- Fundamental
- Price
- IMMP $1.93
- PALI $1.96
- Analyst Decision
- IMMP Buy
- PALI Strong Buy
- Analyst Count
- IMMP 1
- PALI 2
- Target Price
- IMMP $7.00
- PALI $12.00
- AVG Volume (30 Days)
- IMMP 208.1K
- PALI 10.3M
- Earning Date
- IMMP 10-10-2025
- PALI 11-11-2025
- Dividend Yield
- IMMP N/A
- PALI N/A
- EPS Growth
- IMMP N/A
- PALI N/A
- EPS
- IMMP N/A
- PALI N/A
- Revenue
- IMMP $3,306,742.00
- PALI N/A
- Revenue This Year
- IMMP $16.82
- PALI N/A
- Revenue Next Year
- IMMP N/A
- PALI N/A
- P/E Ratio
- IMMP N/A
- PALI N/A
- Revenue Growth
- IMMP 31.28
- PALI N/A
- 52 Week Low
- IMMP $1.32
- PALI $0.53
- 52 Week High
- IMMP $2.71
- PALI $3.44
- Technical
- Relative Strength Index (RSI)
- IMMP 45.60
- PALI 61.09
- Support Level
- IMMP $1.88
- PALI $1.61
- Resistance Level
- IMMP $2.08
- PALI $2.14
- Average True Range (ATR)
- IMMP 0.10
- PALI 0.17
- MACD
- IMMP -0.03
- PALI -0.01
- Stochastic Oscillator
- IMMP 4.97
- PALI 70.09
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.